JP2010523632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523632A5 JP2010523632A5 JP2010502559A JP2010502559A JP2010523632A5 JP 2010523632 A5 JP2010523632 A5 JP 2010523632A5 JP 2010502559 A JP2010502559 A JP 2010502559A JP 2010502559 A JP2010502559 A JP 2010502559A JP 2010523632 A5 JP2010523632 A5 JP 2010523632A5
- Authority
- JP
- Japan
- Prior art keywords
- terminus
- compound according
- medicament
- manufacture
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000007026 protein scission Effects 0.000 claims 4
- 239000004066 vascular targeting agent Substances 0.000 claims 4
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0707034.5A GB0707034D0 (en) | 2007-04-12 | 2007-04-12 | Compounds |
| GB0707034.5 | 2007-04-12 | ||
| PCT/GB2008/001043 WO2008125800A2 (en) | 2007-04-12 | 2008-03-27 | Mmp activated vascular disrupting agents |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014090991A Division JP5931952B2 (ja) | 2007-04-12 | 2014-04-25 | 化合物 |
| JP2014090990A Division JP5911908B2 (ja) | 2007-04-12 | 2014-04-25 | 化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010523632A JP2010523632A (ja) | 2010-07-15 |
| JP2010523632A5 true JP2010523632A5 (enExample) | 2011-05-12 |
| JP5537413B2 JP5537413B2 (ja) | 2014-07-02 |
Family
ID=38116587
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010502559A Expired - Fee Related JP5537413B2 (ja) | 2007-04-12 | 2008-03-27 | 化合物 |
| JP2014090990A Expired - Fee Related JP5911908B2 (ja) | 2007-04-12 | 2014-04-25 | 化合物 |
| JP2014090991A Expired - Fee Related JP5931952B2 (ja) | 2007-04-12 | 2014-04-25 | 化合物 |
| JP2016088836A Expired - Fee Related JP6170590B2 (ja) | 2007-04-12 | 2016-04-27 | 化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014090990A Expired - Fee Related JP5911908B2 (ja) | 2007-04-12 | 2014-04-25 | 化合物 |
| JP2014090991A Expired - Fee Related JP5931952B2 (ja) | 2007-04-12 | 2014-04-25 | 化合物 |
| JP2016088836A Expired - Fee Related JP6170590B2 (ja) | 2007-04-12 | 2016-04-27 | 化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8691751B2 (enExample) |
| EP (4) | EP2481429B1 (enExample) |
| JP (4) | JP5537413B2 (enExample) |
| CY (1) | CY1120368T1 (enExample) |
| DK (3) | DK2481428T3 (enExample) |
| ES (3) | ES2573228T3 (enExample) |
| GB (1) | GB0707034D0 (enExample) |
| HK (1) | HK1258466A1 (enExample) |
| HR (1) | HRP20181043T1 (enExample) |
| HU (3) | HUE038633T2 (enExample) |
| LT (1) | LT2481429T (enExample) |
| PL (3) | PL2134372T3 (enExample) |
| PT (1) | PT2481429T (enExample) |
| SI (1) | SI2481429T1 (enExample) |
| TR (1) | TR201807811T4 (enExample) |
| WO (1) | WO2008125800A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0707034D0 (en) | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
| GB0819287D0 (en) * | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| GB2516882A (en) * | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
| US9169337B2 (en) | 2014-03-12 | 2015-10-27 | Chevron Phillips Chemical Company Lp | Polymers with improved ESCR for blow molding applications |
| NZ731185A (en) * | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| GB2545169B (en) * | 2015-12-01 | 2019-10-09 | Ellipses Pharma Ltd | Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site |
| EP3648752B1 (en) | 2017-07-07 | 2024-01-17 | Katholieke Universiteit Leuven | Treatment of avascular or hypovascular micro-tumors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200202183T2 (tr) * | 2000-03-15 | 2007-01-22 | Bristol-Myers Squibb Pharma Company | Peptidazla bölünebilen, hedeflenmiş antineoplastik ilaçlar ve terapetik kullanımları |
| GB0018240D0 (en) * | 2000-07-25 | 2000-09-13 | Pharmacia & Upjohn Spa | Polymeric conjugates of antitumor agents |
| GB0105929D0 (en) * | 2001-03-09 | 2001-04-25 | Btg Int Ltd | Physiologically activated prodrugs |
| ES2544527T3 (es) * | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
| US20050106100A1 (en) | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| US8420603B2 (en) | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| NZ556065A (en) * | 2005-01-24 | 2009-04-30 | Univ Texas | FC-fusion constructs binding to phosphatidylserine and their therapeutic use |
| EP1862470A4 (en) | 2005-02-25 | 2010-04-21 | Univ Hokkaido Nat Univ Corp | A BLOODED ELEMENT WHICH IS SELECTLY Degraded in TUMOR TISSUE |
| US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| GB0707034D0 (en) * | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
| GB0819287D0 (en) * | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| GB2516882A (en) | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
-
2007
- 2007-04-12 GB GBGB0707034.5A patent/GB0707034D0/en not_active Ceased
-
2008
- 2008-03-27 TR TR2018/07811T patent/TR201807811T4/tr unknown
- 2008-03-27 EP EP12160565.3A patent/EP2481429B1/en not_active Not-in-force
- 2008-03-27 LT LTEP12160565.3T patent/LT2481429T/lt unknown
- 2008-03-27 ES ES08718877.7T patent/ES2573228T3/es active Active
- 2008-03-27 US US12/595,482 patent/US8691751B2/en active Active
- 2008-03-27 HU HUE12160565A patent/HUE038633T2/hu unknown
- 2008-03-27 PL PL08718877.7T patent/PL2134372T3/pl unknown
- 2008-03-27 PT PT121605653T patent/PT2481429T/pt unknown
- 2008-03-27 EP EP12160556.2A patent/EP2481428B1/en not_active Not-in-force
- 2008-03-27 DK DK12160556.2T patent/DK2481428T3/en active
- 2008-03-27 ES ES12160556.2T patent/ES2573682T3/es active Active
- 2008-03-27 WO PCT/GB2008/001043 patent/WO2008125800A2/en not_active Ceased
- 2008-03-27 PL PL12160565T patent/PL2481429T3/pl unknown
- 2008-03-27 EP EP18156526.8A patent/EP3348282A1/en not_active Withdrawn
- 2008-03-27 HU HUE12160556A patent/HUE029080T2/en unknown
- 2008-03-27 ES ES12160565.3T patent/ES2683168T3/es active Active
- 2008-03-27 HU HUE08718877A patent/HUE027528T2/en unknown
- 2008-03-27 SI SI200831959T patent/SI2481429T1/en unknown
- 2008-03-27 JP JP2010502559A patent/JP5537413B2/ja not_active Expired - Fee Related
- 2008-03-27 EP EP08718877.7A patent/EP2134372B1/en not_active Not-in-force
- 2008-03-27 PL PL12160556.2T patent/PL2481428T3/pl unknown
- 2008-03-27 DK DK08718877.7T patent/DK2134372T3/en active
- 2008-03-27 DK DK12160565.3T patent/DK2481429T3/en active
-
2013
- 2013-12-17 US US14/109,333 patent/US9358303B2/en not_active Expired - Fee Related
-
2014
- 2014-04-25 JP JP2014090990A patent/JP5911908B2/ja not_active Expired - Fee Related
- 2014-04-25 JP JP2014090991A patent/JP5931952B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-27 JP JP2016088836A patent/JP6170590B2/ja not_active Expired - Fee Related
- 2016-05-06 US US15/148,368 patent/US9956296B2/en active Active
-
2018
- 2018-03-16 US US15/923,564 patent/US10556014B2/en not_active Expired - Fee Related
- 2018-06-27 CY CY20181100663T patent/CY1120368T1/el unknown
- 2018-07-05 HR HRP20181043TT patent/HRP20181043T1/hr unknown
-
2019
- 2019-01-16 HK HK19100772.3A patent/HK1258466A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523632A5 (enExample) | ||
| JP7490735B2 (ja) | ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法 | |
| JP7659015B2 (ja) | 免疫調節剤としての１，２，４－オキサジアゾールおよびチアジアゾール化合物 | |
| CN113861268B (zh) | 细胞穿透肽及其制备和使用方法 | |
| JP2012506408A5 (enExample) | ||
| JP2020063241A5 (enExample) | ||
| JP5908000B2 (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| CN104519902B (zh) | 双酰化glp‑1衍生物 | |
| US9545449B2 (en) | Site-specific labeling and targeted delivery of proteins for the treatment of cancer | |
| CY1121781T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων | |
| CA2367755A1 (en) | Dimeric compounds and their use as inhibitors of neuraminidase | |
| WO2010136474A3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| JP2013525080A5 (enExample) | ||
| WO2009075859A3 (en) | Formulation of insulinotropic peptide conjugates | |
| CA3166816A1 (en) | Il-7r.alpha..gamma.c binding compounds | |
| TW201043601A (en) | Substituted aromatic compounds and pharmaceutical uses thereof | |
| TW202500573A (zh) | 細胞穿透肽序列 | |
| JP2020097605A (ja) | 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション | |
| JP2020500871A (ja) | 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生 | |
| US9556229B2 (en) | Modification of peptides using a bis(thioether)arylbridge approach | |
| JP2013542954A5 (enExample) | ||
| WO2006125621A8 (en) | Substituted piperidines as renin inhibitors | |
| JP5341521B2 (ja) | タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法 | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| WO2015076359A1 (ja) | プロテアソーム阻害性化合物 |